<DOC>
	<DOCNO>NCT02975557</DOCNO>
	<brief_summary>The objective study establish whether patient dry eye disease ( DED ) able tolerate receive Brimonidine : 0.15 % eye drop two time day twelve week ( primary tolerability objective ) investigate preliminary efficacy Brimonidine 0.15 % topical eye drop solution treat MGD ( primary efficacy objective ) . Meibomian Gland dysfunction happen numerous condition Rosacea , Sjögren 's syndrome , oGVHD . In order limit influence differ etiology outcome trial , investigator limit screen MGD accompanies oGVHD .</brief_summary>
	<brief_title>Brimonidine Eye Drops Treatment Ocular Graft-vs-Host Disease ( oGVHD )</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Lubricant Eye Drops</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>1 . Aged 18 year old . 2 . Capable give informed consent provide inform consent . 3 . Diagnosis Meibomian Gland Disease 4 . Women must postmenopausal ≥ 1 year , surgically sterilize . If , negative urine pregnancy test require within 7 day participant receive first dose study drug along definite evidence contraceptive use duration study . Women reproductive age use method birth control acceptable participant study doctor . This may include oral contraceptive pill , birth control implant , barrier method abstinence . If participant suspect pregnancy enrol , another pregnancy test administer . If test positive , participant discontinue study immediately . 1 . Allergic Brimonidine similar product , excipients Brimonidine 2 . Currently receive Brimonidine preparation part glaucoma management 3 . Receiving receive within 30 day experimental systemic medication . 4 . Active ocular infection ocular allergy . 5 . Any history eyelid surgery ocular surgery within past 3 month . 6 . Corneal epithelial defect large 1 mm2 either eye . 7 . Have active drug/alcohol dependence abuse history . 8 . Vulnerable population , neonate , pregnant woman , child , prisoner , institutionalized individual , others may consider vulnerable population .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Brimonidine</keyword>
	<keyword>Dry Eye</keyword>
	<keyword>oGVHD</keyword>
	<keyword>MGD</keyword>
</DOC>